10x Genomics, Inc. TXG recently began commercial shipments of Atera, its next-generation spatial biology platform designed to combine whole-transcriptome analysis, sub-cellular resolution and single-cell sensitivity at scale. The launch marks a commercialization milestone as demand for Atera has exceeded the company’s initial 2026 shipment expectations, with booked orders surpassing 40 instruments.
Per management, the strong response to Atera and the breadth of studies being planned reinforce its potential to transform biological research. The company believes Atera can help researchers overcome biological complexity, accelerate disease understanding and support the development of better treatments.
Michael Schnall-Levin, chief technology officer, chief strategy officer and founding scientist at 10x Genomics, noted that Atera was developed by rethinking conventional limitations from first principles. The initial commercial launch represents the foundation for further enhancements intended to broaden Atera’s capabilities and applications.
TXG Stock Trend Following the News
Following the announcement, TXG stock gained 1.7% at yesterday’s close. Year to date, the stock skyrocketed 452.1%, outperforming the industry’s 19.6% growth and the S&P 500’s 11.9% gain.
The commercial rollout of Atera could strengthen TXG’s growth by expanding its exposure to large-scale research programs and creating opportunities for higher recurring consumables and service revenues. Broader use across academic, translational and biopharma research could also deepen customer relationships and support greater utilization of the company’s technology ecosystem. Strong initial demand provides an important early indicator for the platform’s revenue contribution as shipments scale.
TXG currently has a market capitalization of $11.53 billion.
Image Source: Zacks Investment Research
More on Atera’s Spatial Biology Capabilities
Atera is designed to address limitations associated with the scale and depth of spatial studies by enabling researchers to analyze whole-transcriptome information while retaining single-cell sensitivity and sub-cellular resolution. The platform is being positioned for applications ranging from tissue atlasing and disease-mechanism research to biomarker discovery, therapeutic-response studies and generation of large biological datasets for artificial intelligence models.
Early research programs illustrate the breadth of potential applications. Researchers at the Allen Institute used Atera during early access to profile human skin and duodenum tissue, generating spatial datasets covering more than 350,000 cells combined. The institute plans to deploy three Atera instruments across immunology, neuroscience and synthetic biology research.
Atera is gaining traction in translational and biopharma research. The University of Texas MD Anderson Cancer Center plans to use Atera for cancer research, including efforts to generate spatial datasets that could help researchers study treatment response and resistance. Nearly all of the world’s 20 largest R&D-spending biopharma companies have either purchased systems or accessed Atera through its Catalyst Research Services. The ASTRA consortium plans to use Atera to expand its pan-cancer spatial atlas from 2,000 to 5,000 tumors over the next two years.
10x Genomics is further expanding access through Catalyst Research Services, where projects have been booked by more than 100 customers within five months. The company plans to use Atera-generated data to support AI foundation models, including efforts by Biohub to create datasets for predicting cellular responses to genetic and pharmacologic perturbations.
TXG is also developing an Atera roadmap that includes automated slide preparation, RNA-protein multiomics and in-situ mutation detection. These planned capabilities could expand the range of molecular information researchers can analyze within the same tissue architecture.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global spatial transcriptomics market is estimated to reach $495.2 million in 2026 and is projected to expand at a 14.7% CAGR through 2033.
Factors such as increasing R&D in spatial omics, advances in sequencing technologies, rising interest in tissue-level molecular analysis and growing applications in disease research are supporting market growth.
Other News
10x Genomics recently announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes. The platform is currently in early access and is expected to launch commercially in early 2027.
In late July, 10x Genomics announced a multi-year research collaboration with Lausanne University Hospital to advance cancer diagnostics using single-cell and spatial technologies. The study will analyze tumors across multiple solid cancers to identify biomarkers predicting treatment response and resistance, supporting personalized treatment decisions and future diagnostic applications.
10x Genomics Price
10x Genomics price | 10x Genomics Quote
TXG’s Zacks Rank & Key Picks
Currently, 10x Genomics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veracyte VCYT, Globus Medical GMED and Intuitive Surgical ISRG.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
10x Genomics (TXG): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).